Eton Pharmaceuticals, Inc. (ETON) Gross Margin
- Gross margin · 12 months: Value 57.87%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 57.87% | Gross profit / revenue. Period ending 2026-06-30. $61.10M ÷ $105.59M × 100 ≈ 57.87% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 61.10M USD | Gross Profit |
| Revenue | 105.59M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 44.49M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $61.10M | $105.59M | $44.49M | 57.87% |
| 2026-03-31 | $47.61M | $86.93M | $39.32M | 54.77% |
| 2025-12-31 | $42.74M | $79.95M | $37.21M | 53.46% |
| 2025-09-30 | $36.12M | $70.32M | $34.20M | 51.36% |
| 2025-06-30 | $34.56M | $58.18M | $23.62M | 59.41% |
| 2025-03-31 | $28.27M | $48.33M | $20.06M | 58.49% |
| 2024-12-31 | $23.41M | $39.01M | $15.60M | 60.01% |
| 2024-09-30 | $20.57M | $34.68M | $14.11M | 59.30% |
| 2024-06-30 | $18.67M | $31.38M | $12.71M | 59.48% |
| 2024-03-31 | $22.72M | $34.30M | $11.58M | 66.24% |
| 2023-12-31 | $21.06M | $31.64M | $10.58M | 66.56% |
| 2023-09-30 | $23.79M | $32.83M | $9.04M | 72.47% |
| 2023-06-30 | $21.41M | $29.02M | $7.61M | 73.77% |
| 2023-03-31 | $16.34M | $24.38M | $8.04M | 67.01% |
| 2022-12-31 | $14.32M | $21.25M | $6.93M | 67.38% |
| 2022-09-30 | $13.88M | $18.85M | (m) | 73.67% |
| 2022-06-30 | $11.99M | $16.40M | (m) | 73.08% |
| 2022-03-31 | $10.36M | $12.11M | (m) | 85.54% |
| 2021-12-31 | $19.21M | $21.83M | (m) | 87.99% |
| 2021-09-30 | $13.18M | $15.82M | (m) | 83.29% |
| 2021-06-30 | $13.00M | $14.88M | $1.88M | 87.36% |
| 2021-03-31 | $10.06M | $11.84M | $1.77M | 85.01% |
| 2020-12-31 | $-247.00K | $39.00K | $286.00K | -633.33% |
| 2020-09-30 | $-22.00K | $417.00K | (m) | -5.28% |
| 2020-06-30 | $-5.00K | $578.00K | (m) | -0.87% |
| 2020-03-31 | $3.00K | $558.00K | (m) | 0.54% |
| 2019-12-31 | $506.00K | $959.00K | $453.00K | 52.76% |
| 2019-09-30 | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |